Amedisys — Q4 2022 Earnings Presentation
21 slides from Amedisys's earnings presentation, Feb 15, 2023
Slide 1: Amedisys Fourth Quarter 2022 Earnings Call Supplemental Slides
1 Amedisys Fourth Quarter 2022 Earnings Call Supplemental Slides February 16th, 2023 Exhibit 99.2
Slide 2: Forward-Looking Statements
2 This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could c
Slide 3: Our Key Areas of Focus
3 OUR KEY AREAS OF FOCUS Strategic areas of focus and progress made during Q4’22 • Home Health*: Total same store admissions +5% • Hospice: Total same store admissions -8%, ADC -2% • Personal Care: PC Network drove ~$286K in revenue to Home Health and Hospice via care coordination • High Acuity Care
Slide 4: Highlights and Summary Financial Results (Adjusted): 4Q22
4 HIGHLIGHTS AND SUMMARY FINANCIAL RESULTS (ADJUSTED): 4Q 2022(1) Home Health total same store admissions +5%; Hospice same store admissions -8%; EBITDA margin decline driven by our acquisitions (additional $4M in losses over Q4’21), the return of sequestration (Q4’21 benefited by $9M), planned wage
Slide 5: Revenue Mix and Reimbursement by Payor
5 65.0% 11.7% 23.3% Home Health Revenue Medicare FFS Private Episodic Per Visit 61.0% 35.2% 2.8% 1.0% Amedisys Consolidated Revenue Home Health Hospice Personal Care High Acuity Care • Medicare FFS: Reimbursed for a 30-day period of care • Private Episodic: MA and Commercial plans who reimburse us f
Slide 6: Home Health and Hospice Segment (Adjusted) – Q4 2022
6 HOME HEALTH AND HOSPICE SEGMENT (ADJUSTED) – Q4 2022(1) • Revenue per Episode up 1.3% (primarily due to +3.2% rate increase partially offset by the reinstatement of sequestration at 2% (~$5M)) • Y/Y Total CPV up $7.99 (+7.5%, primarily due to raises, wage inflation, an increase in salaried employe
Slide 7: General & Administrative Expenses – Adjusted
7 4Q21 1Q22 2Q22 3Q22 4Q22 Salary and Benefits 21.7 23.8 23.3 22.1 24.0 Other 10.4 10.2 6.7 12.2 11.7 Corp. G&A Subtotal 32.1 34.0 30.1 34.3 35.7 Non-cash comp 4.0 1.6 2.6 1.2 2.3 Adjusted Corporate G&A 36.1 35.6 32.7 35.5 38.0 $ in Millions 4Q21 1Q22 2Q22 3Q22 4Q22 Home Health Segment - Total 84.7
Slide 8: Operational Excellence: Home Health Cost Per Visit
8 OPERATIONAL EXCELLENCE: HOME HEALTH COST PER VISIT (CPV)-ADJUSTED YOY Total CPV impacted by labor cost pressures and lower visits *Note: Direct comparison with industry competitors CPV calculation $25.00 $50.00 $75.00 $100.00 4Q21 3Q22 4Q22 Cost Per Visit (CPV) Salaries Contractors Benefits Transp
Slide 9: Driving Top Line Growth
9 DRIVING TOP LINE GROWTH Home Health admissions growth remains strong; volume impacted by mix shift. Sequential average daily census decline due to softer admission volumes and seasonality. 2% 0% -2% 1% 1% 2% 2% 0% 5% 5% -4.0% -2.0% 0.0% 2.0% 4.0% 6.0% 50,000 100,000 150,000 4Q21 1Q22 2Q22 3Q22 4Q2
Slide 10: Industry Leading Quality Scores
10 INDUSTRY LEADING QUALITY SCORES Quality of Patient Care (QPC) Patient Satisfaction (PS) • Amedisys maintains a 4-Star average in the Apr 2023 HHC Preview with 99% of our providers (representing 99% of care centers) at 4+ Stars and 82% of our providers (representing 83% of care centers) at 4.5+ St
Slide 11: Hospice Quality: Moving Towards Best-in-Class
11 HOSPICE QUALITY: AMEDISYS HOSPICE CONTINUES TO MOVE TOWARDS BEST-IN-CLASS Hospice Quality Notes: Included in the above analysis are only active providers. Exhibit 99.2
Slide 12: Debt and Liquidity Metrics
12 DEBT AND LIQUIDITY METRICS Net leverage ~1.5x 1. Net debt defined as total debt outstanding ($438.4M) less cash ($54.1M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($262.1M). 3. Liquidity defined as the sum of cash balance and available revolving
Slide 13: Cash Flow Statement Highlights
13 CASH FLOW STATEMENT HIGHLIGHTS (1) Total cash flow from operations for 2022 of $133M. Results impacted by repayment of deferred payroll taxes ($27M) in Q4-22 and ZPIC audit repayment ($38M). 1. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt
Slide 14: Income Statement Adjustments
14 INCOME STATEMENT ADJUSTMENTS (1) 1. The financial results for the three-month periods ended December 31, 2021, March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these no
Slide 15: 2023 Guidance
15 2023 Guidance Exhibit 99.2
Slide 16: Amedisys 2023 Preliminary Guidance
16 AMEDISYS 2023 PRELIMINARY GUIDANCE Revenue, EBITDA and EPS guidance ranges for FY 2023 ($M except for EPS) Total AMED Adjusted Revenue $2,244 - $2,274 Adjusted EBITDA $230 - $240 Adjusted EPS $4.13 - $4.36 Exhibit 99.2
Slide 17: 2022 – 2023 EBITDA Waterfall
17 2022 – 2023 EBITDA WATERFALL Category Description Reimbursement, Net Home Health rate update: 0%, Hospice rate update: +3.8% Sequestration Headwind of $13M from 2022 to 2023 Compensation & Benefits Impact of 2022 raises (Aug 2022) plus 4% for 2023 raises and wage inflation; Benefits increase refl
Slide 18: 2023 Guidance Considerations
18 2023 Guidance Considerations Amedisys Consolidated • Tax rate ~27% • Cash tax rate ~19% • Diluted share count ~32.9 million shares • Capital Expenditures ~$13- $15 million • Salary increases and wage inflation ~4% • Benefits increase (including enhancements to medical and disability plans and new
Slide 19: 2023 High Acuity Segment Revenue
19 2023 HIGH ACUITY SEGMENT REVENUE ($ in millions) 2023A to 2023P Revenue Bridge 2022 → 2023 Revenue Growth: 3.9x $47 2023 Revenue Composition by Clinical Program (1) Excludes $6M of 2022 revenue to be reported in Home Health segment in 2023 (2) $47M represents the high end of the $27M - $47M range
Slide 20: Environmental, Social, Governance (E.S.G.) Considerations
20 Environmental, Social, Governance (E.S.G.) Considerations Exhibit 99.2
Slide 21: Environmental, Social, Governance (E.S.G.) Considerations
21 ENVIRONMENTAL, SOCIAL, GOVERNANCE (E.S.G.) CONSIDERATIONS Sustainable, high-quality, patient focused, home-based care model Environmental • Amedisys is dedicated to the sustainability of our business and the communities in which we serve • Environmental health has a strong correlation with physic